According to the Catalogue of Somatic Mutations in Cancer (COSMIC), which provides access to comprehensive human tumor mutation databases, KRAS mutations were expressed in about 22% of analyzed tumors, versus 8% for NRAS and 3% for HRAS [25]. Here, KRAS is linked to neoplasm.